K-ras mutation is an early event, and various studies have identified its presence in biopsy specimens or different biological samples from pancreatic cancer patients; however, this team developed a new strategy for its detection, from fecal samples of patients with different benign or malign pancreatic diseases. This evidence concerns the gene KRAS and pancreatic neoplasm.